On November 3, 2023, Outlook Therapeutics, Inc. was sued for violations of the federal securities laws in the United States District Court for the District of New Jersey on behalf of investors who purchased or otherwise
acquired Outlook securities between December 29, 2022 and August 29, 2023, both dates inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.